WCLC 2025 - Posters & ePosters-EP.12.66 Beta Catenin (CTNNB1) Mutations in Non-Small Cell Lung Cancer (NSCLC): Clinical Characteristics and Efficacy of Antiangiogenic Therapy

EP.12.66 Beta Catenin (CTNNB1) Mutations in Non-Small Cell Lung Cancer (NSCLC): Clinical Characteristics and Efficacy of Antiangiogenic Therapy

Back to course

Pdf Summary

This retrospective observational study (2020–2025) analyzed non-small cell lung cancer (NSCLC) patients harboring beta-catenin (CTNNB1) mutations to assess clinical characteristics and the efficacy of antiangiogenic therapy, particularly anti-VEGF treatment. From 1876 lung cancer patients, 43 had CTNNB1 mutations, with 35 diagnosed with NSCLC. CTNNB1, a key Wnt pathway component linked to tumor progression and response to antiangiogenics in other cancers, has an unclear prognostic role in NSCLC.<br /><br />Results showed that first-line systemic therapy in CTNNB1-mutant NSCLC yielded an overall response rate (ORR) of 45% and median progression-free survival (mPFS) of 5.7 months for non-oncogene-addicted patients. Those with concurrent EGFR mutations attained a higher ORR of 60% and a longer mPFS of 13.5 months. Notably, 37% of patients received second- or later-line platinum-based chemotherapy combined with bevacizumab (an anti-VEGF agent), achieving an ORR of 88.9% and mPFS of 8 months overall; in the EGFR-mutated subgroup, mPFS was 10.1 months.<br /><br />Median overall survival (OS) was higher in patients treated with antiangiogenic therapy (44.2 months) compared to those without (18.8 months), though this difference did not reach statistical significance (p=0.37). The data suggest that CTNNB1 mutations may negatively affect NSCLC treatment response; however, adding anti-VEGF therapy could provide a survival benefit and represent a promising treatment approach for this subset.<br /><br />The study’s limitations include patient heterogeneity and the retrospective design, indicating the need for larger prospective studies to confirm findings and better define CTNNB1’s prognostic and predictive roles in NSCLC and antiangiogenic therapy efficacy.

Asset Subtitle

David Pelegrina

Meta Tag

Speaker David Pelegrina

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

non-small cell lung cancer

NSCLC

CTNNB1 mutation

beta-catenin

antiangiogenic therapy

anti-VEGF treatment

overall response rate

progression-free survival

EGFR mutation

bevacizumab